Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4028 clinical trials
featured
COVID-19 Treatment Trial: Investigational Medication as a Non-antiviral Immunomodulator

. - Arm A: CD24Fc / Best Available Treatment - Arm B: placebo / Best Available Treatment  CD24Fc will be administered as single dose of 480 mg via IV infusion on

  • 3989 views
  • 17 Jun, 2020
  • 4 locations
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will

myeloid neoplasm
FGFR1
lymphoid malignancy
  • 79 views
  • 14 Dec, 2020
  • 35 locations
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients with Generalized Myasthenia Gravis IND 140,115 STUDY NUMBER: ALXN1210-MG-306

Primary To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Myasthenia Gravis-Activities of Daily Living (MG

mycophenolate mofetil
edrophonium chloride test
repetitive nerve stimulation
edrophonium chloride
cyclophosphamide
  • 187 views
  • 24 Nov, 2020
  • 1 location
featured
Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.  

  • 51 views
  • 22 Feb, 2019
  • 1 location
featured
Randomized, Double-Blind, Parallel-Group, Multi-center study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with AS who are randomized to dose escalation after not achieving inactive disease during an initial 16 weeks of open-label tx w/secukinumab 150 mg (ASLeap)

Randomized, Double-Blind, Parallel-Group, Multi-center study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with AS who are randomized to dose escalation

secukinumab
  • 120 views
  • 23 Nov, 2020
  • 1 location
featured
A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of atogepant for the prevention of chronic migraines (PROGRESS)

To evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg once daily for the prevention of chronic migraine (CM).  

  • 43 views
  • 10 May, 2019
  • 1 location
featured
NASH001 - Non-alcoholic Steatohepatitis (NASH) - CC-90001-NASH-001 - US  

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001 (100 mg, 200 mg

  • 85 views
  • 05 Jan, 2021
  • 37 locations
featured
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Larazotide for Relief of Persistent Symptoms in Patients with Celiac Disease on a Gluten Free Diet

To assess the efficacy and safety of larazotide 0.25 mg or larazotide 0.50 mg TID versus placebo for the relief of persistent symptoms in adult patients with celiac disease on

larazotide
gluten
  • 41 views
  • 23 Nov, 2020
  • 1 location
featured
Add-On Treatment for Schizophrenia Symptom Management

The primary objective of this study is to evaluate the effectiveness of NaBen® (sodium benzoate) (1000 mg/day) compared to Placebo (0 mg/day), in improving symptoms associated with

  • 42 views
  • 23 Nov, 2020
  • 1 location
featured
A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent

  • 54 views
  • 23 Nov, 2020
  • 1 location